3 Overhyped Cannabis Stocks to Avoid Today

Hexo Corp. (TSX:HEXO)(NYSE:HEXO), Canopy Growth Corp. (TSX:WEED)(NYSE:CGC), and Cronos Group Inc. (TSX:CRON)(NASDAQ:CRON) are riding on the marijuana hype but hasn’t delivered the expected gains to investors.

Everyone was expecting that the legalization of adult-use marijuana would create a “supernova” on the stock market. There was a stellar explosion but only in the valuations of the cannabis companies.

People are starting to realize that cannabis stocks are overhyped. The sky-high valuations are coming down and the period of reckoning is at hand. Hexo (TSX:HEXO)(NYSE:HEXO), Canopy Growth (TSX:WEED)(NYSE:CGC), and Cronos (TSX:CRON)(NASDAQ:CRON) are the overhyped cannabis stocks you should avoid.

Hard sell mode

The medical application of marijuana as pain management in various illnesses is enough to heighten interest among pot stock investors. There’s no need to prop up this market that could reach US$148.35 billion by 2028

But Hexo wants to exploit the marijuana craze and be on the spotlight. The cannabis grower entered into a joint venture with Molson Coors Brewing. Because of the perceived medical benefits of cannabidiol (CBD), the two companies announced plans to introduce CBD-infused beverages.

Hexo believes that non-alcoholic CBD-infused beverages would be a big hit. Meanwhile, Molson Coors is banking on the enormous potential sales of this new line of drinks to offset the weakening beer sales.

Canopy Growth was able to entice beer giant Constellation Brands to invest $4 billion and become a partner in its quest to gain a significant share of the CBD beverages market. Hexo and Canopy are on hard sell mode when Health Canada has yet to legalize CBD-infused beverages and other derivatives.

The tentative launch date of the new products is December this year. However, Hexo and Canopy are entering a crowded space with big names like Anheuser-Busch InBev joining the fray. Sales could go flat as the stiff competition would lower prices and drive down profit margins.

Still, the first hurdle is the legalization by the regulatory agency.

Overpriced cannabis stocks

The industry heavyweights along with the second-tier cannabis operators are in a tailspin since April of this year. Investment analysts agree that cannabis stocks are overvalued and overpriced.

After sealing a deal with global tobacco giant Altria, Cronos had the resources to gain substantial market share, and its stock price rose to as high as $31.77 in early March. But the high growth didn’t come, which was a big disappoint to eager investors. As of this writing, CRON is down 51.36% to $15.45 from the said high.

Cronos is overvalued compared with industry peers. The $1.8 billion Altria investment was the main reason for its sky-high valuation. Thus far in 2019, Cronos is reporting sub-par financial results.  Cronos is undeserving of the premium valuation it enjoys today.

The company needs to accelerate growth because it has the slowest year-over-year revenue growth in the industry.

High risk, high reward

The depressed prices of Hexo, Canopy Growth, and Cronos are tempting but be very cautious. There’s a strong potential these cannabis stocks will deliver high returns to you in the future. However, let the companies execute the respective strategies first and not rely on the hype.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned. The Motley Fool owns shares of Molson Coors Brewing.

More on Cannabis Stocks

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Should You Buy Canopy Growth Stock or Green Thumb Stock Today?

Let's dive into two cannabis giants, and which one may be the better pick for long-term investors.

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Could Aurora Cannabis Stock Finally Recover by Year-End?

Down 99% from all-time highs, Aurora Cannabis stock is focused on improving profit margins and expanding sales of its medical…

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Are Pot Stocks About to Surge Again? 

With pot stocks making big moves of late, many investors are now asking whether the cannabis sector is worth investing…

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Can Pot Stocks Aurora Cannabis and Canopy Growth Bounce Back in Q4?

Down over 99% from all-time highs, Canadian pot stocks such as Aurora Cannabis and Canopy Growth remain high-risk bets.

Read more »

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Can Canopy Growth Stock Finally Recover in 2024?

Down 98% from all-time highs, Canopy Growth remains a high-risk investment in 2024 given its weak fundamentals.

Read more »

Tech Stocks

3 No-Brainer Stocks to Buy With $20 Right Now

These three stocks are easy buys for those who don't have all that much to spend, and want long-term growth…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Slow Burn: Is Aurora Cannabis Finally a Good Buy in June?

One of the benefits of choosing from some of the most beaten-down market segments like cannabis is that even a…

Read more »

Caution, careful
Cannabis Stocks

I Wouldn’t Touch This TSX Stock With a 60-Foot Pole

I wouldn't touch Canopy Growth Corp (TSX:WEED) stock with a 60-foot pole.

Read more »